The future of market access belongs to organizations that plan years in advance.
In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity, explains why pharmaceutical companies must prepare now for major market access changes coming in Europe and beyond. He highlights that Joint Clinical Assessments for rare disease assets, beginning in 2028, will require earlier planning, stronger governance, and more integrated evidence-generation strategies. Steve also discusses the complexity created by varying country-specific care pathways, limited comparators, and the growing importance of real-world evidence in rare disease development. Across policy shifts like JCA, IRA, MFN, and new European pharmaceutical legislation, the central message is clear: organizations that anticipate earlier will be better positioned to succeed.
Tune in to hear how the future of rare disease market access is being reshaped, and why companies that prepare earlier will have a major strategic advantage!
Resources:
Connect with and follow Steve Mather on LinkedIn.
Follow Lumanity on LinkedIn and explore their website!
Learn more about this series we're doing with Lumanity here: https://lumanity.com/commercialization-podcasts/
Podden och tillhörande omslagsbild på den här sidan tillhör
Saul Marquez. Innehållet i podden är skapat av Saul Marquez och inte av,
eller tillsammans med, Poddtoppen.
